Items where authors include "Waters, JS"

Article

Lamarca, A, Palmer, DH, Wasan, HS et al. (18 more authors) (2021) Second-line FOLFOX chemotherapy for advanced biliary tract cancer – Authors' reply. The Lancet Oncology, 22 (7). e288-e289. ISSN 1470-2045

Hall, PS, Swinson, D, Cairns, DA orcid.org/0000-0002-2338-0179 et al. (32 more authors) (2021) Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer: The GO2 Phase 3 Randomized Clinical Trial. JAMA oncology, 7 (6). pp. 869-877. ISSN 2374-2437

Lamarca, A, Palmer, DH, Wasan, HS et al. (18 more authors) (2021) Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. The Lancet Oncology, 22 (5). pp. 690-701. ISSN 1470-2045

Smyth, EC, Rowley, S, Cafferty, FH et al. (17 more authors) (2019) Safety and Efficacy of the Addition of Lapatinib to Perioperative Chemotherapy for Resectable HER2-Positive Gastroesophageal Adenocarcinoma: A Randomized Phase 2 Clinical Trial. JAMA Oncology, 5 (8). pp. 1181-1187. ISSN 2374-2437

Backen, AC, Lopes, A, Wasan, H et al. (16 more authors) (2018) Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial. British Journal of Cancer, 119 (1). pp. 27-35. ISSN 0007-0920

Proceedings Paper

Hall, PS, Swinson, D, Waters, JS et al. (17 more authors) (2019) Optimizing chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC): The GO2 phase III trial. In: Journal of Clinical Oncology. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), 31 May - 04 Jun 2019, Chicago, USA. American Society of Clinical Oncology .